Lung Cancer News and Research

Latest Lung Cancer News and Research

Olympus introduces EZ Shot 2 single-use aspiration needles for Endoscopic Ultrasound procedures

Olympus America Inc. today expanded its medical portfolio by introducing a collection of EZ Shot 2 single-use aspiration needles for Endoscopic Ultrasound (EUS) procedures.The four unique needles offer excellent puncture capability along with an adjustable sheath designed to help physicians more accurately approach the targeted site.

From Evident Corporation - Life Sciences 15 Dec 2011

DCC gene protects mice from onset of colon cancer

The research team at Lyon has developed an animal model carrying a mutation of the DCC gene. Mice carrying the mutation develop tumours, because this gene can no longer induce the death of the cancer cells. This discovery could lead to the development of a new targeted cancer treatment that aims to reactivate the dying of cancer cells.

15 Dec 2011

Chemical disruption to key interaction shown to limit metastasis in test mice

Finding ways to counteract or disrupt the invasive nature of cancer cells, called "metastasis," has been a long-term goal of cancer researchers. Now, researchers at Moffitt Cancer Center in Tampa, Fla., have identified an interactive pathway that regulates metastases in some cancers that may be vulnerable to chemical targeting in order to prevent cancer cell proliferation and tumor growth.

14 Dec 2011

Lifestyle and environmental factors may increase risk of cancer

It has been well established that certain lifestyle habits relate to the risk of certain cancers (e.g., smoking and lung cancer). In a well-done analysis, the authors estimate the proportion of cancer in the population associated with a variety of lifestyle and environmental factors. They find that smoking has, by far, the largest effect on the risk of cancer, with 19.4% of cancer cases in the UK attributable to tobacco use.

14 Dec 2011

Researchers identify interactive pathway that regulates cancer metastasis

14 Dec 2011

Synta's ganetespib shows potent in vitro and in vivo activity against multiple breast cancer types

Synta Pharmaceuticals Corp. Ganetespib shows potent in vitro and in vivo activity against multiple types of breast cancer including HER2-positive, ER/PR positive, triple-negative, and inflammatory breast cancer according to results presented at the San Antonio Breast Cancer Symposium.

13 Dec 2011

Geron commences GRN1005 Phase 2 trial in breast cancer

Geron Corporation today announced the initiation of GRABM-B (GRN1005 Against Brain Metastases - Breast cancer), a Phase 2 clinical trial to evaluate GRN1005 in patients with brain metastases arising from breast cancer.

13 Dec 2011

Syndax announces data from entinostat phase 2 study on HL

Syndax Pharmaceuticals, Inc. announced today that data from ENGAGE 501, a multicenter, phase 2 study, demonstrated entinostat, a novel, oral small molecule inhibitor of class I histone deacetylases, showed activity as a single agent in patients with relapsed or refractory Hodgkin's lymphoma.

12 Dec 2011

People in Northern Ireland less likely to develop cancers

People in Northern Ireland have a lower risk of developing some cancers than those living in the Republic of Ireland, according to the All-Ireland Cancer Atlas - a collaborative publication by the Northern Ireland Cancer Registry at Queen's University Belfast and the National Cancer Registry in Cork.

12 Dec 2011

Report uncovers disparities in cancer incidence and death rates in Australia

Over the past quarter century in Australia, cancer incidence rates have increased while deaths from cancer have steadily decreased. Those are some of the findings of a recent study published early online in the Asia-Pacific Journal of Clinical Oncology.

9 Dec 2011

Women with non-melanoma skin cancers more likely to have smoked cigarettes

Women who have non-melanoma skin cancers are more likely to have smoked cigarettes compared to women without skin cancer, said researchers at Moffitt Cancer Center in Tampa, Fla., who published study results in a recent issue of Cancer Causes & Control.

9 Dec 2011

Positive results from Synta's Ganetespib Phase 2 trial on HER2-positive and triple negative mBC

Synta Pharmaceuticals Corp. - Ganetespib, a potent, second generation Hsp90 inhibitor, has demonstrated clinical activity in heavily pre-treated patients with HER2-positive and triple negative metastatic breast cancer according to Phase 2 clinical trial results presented by researchers from Memorial Sloan-Kettering Cancer Center at the San Antonio Breast Cancer Symposium.

9 Dec 2011

Arsenic in rice worrisome

Studies have shown that rice takes up more arsenic from soil than other crops. Now a new study shows that higher arsenic levels are ingested by women who eat as little as half a cup of cooked rice in a day. Currently, there are no limits on the amount of allowable arsenic in rice in the United States. But the Environmental Protection Agency has set arsenic limits in water of 10 parts per billion.

7 Dec 2011

Aethlon receives approval to begin Hemopurifier study at Sarcoma Oncology Center

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that a cancer research study to test the ex vivo effectiveness of the Aethlon Hemopurifier to capture tumor-secreted exosomes from the blood of advanced-stage cancer patients has received institutional review board approval to begin studies at the Sarcoma Oncology Center, based in Santa Monica, California.

7 Dec 2011

ZIOPHARM receives European patent allowance for palifosfamide to treat cancer

ZIOPHARM Oncology, Inc. announced today that it has received an allowance from the European Patent Office for Patent Application No. 05 821 125.1, entitled "Salts of Isophosphoramide mustard and analogs thereof as anti-tumor agents" with claims directed to pharmaceutical compositions of a novel DNA cross-linker, including palifosfamide and their use in treating cancer.

7 Dec 2011

Cameron says all NHS patients should share their medical data for research

According to British Prime Minister David Cameron, every NHS patient should be a “research patient” with their medical details “opened up” to private healthcare firms. The PM announced that all those who use the NHS in England will be helping in the fight against disease by helping advance research. He hopes the result will be that patients get faster access to new treatments and Britain's life sciences sector will become a world leader.

6 Dec 2011

Genetic variation predicts survival chances of ovarian cancer

Yale Cancer Center researchers have shown that a tiny genetic variation predicts chances of survival and response to treatment for patients with ovarian cancer.

5 Dec 2011

First Edition: December 2, 2011

In today's headlines, reports on congressional efforts to extend a payroll tax break and other work Congress must do before the end of the year -- including the Medicare doc fix.

2 Dec 2011

AVEO, Boehringer Ingelheim enter development and manufacturing agreement for ficlatuzumab

AVEO Pharmaceuticals, Inc. and Boehringer Ingelheim today announced that they have entered into an agreement for large-scale process development and clinical manufacturing of ficlatuzumab, AVEO's novel HGF inhibitory antibody that is currently in Phase 2 clinical development in patients with non-small cell lung cancer.

2 Dec 2011

Idera regains global rights to IMO-2055 from Merck KGaA for treatment of cancer

Idera Pharmaceuticals, Inc. today announced that it has regained global rights to IMO-2055, an agonist of Toll-like Receptor (TLR) 9, as part of an agreed-upon termination of its oncology collaboration with Merck KGaA, Darmstadt, Germany.

1 Dec 2011